Vitiligo
A Journey Toward Healing and Peace of Mind
Vitiligo is a condition that affects the skin, but it also has a profound emotional impact, often influencing self-confidence and social relationships. At the Dermacademy Institute, we are fully aware of the psychological and relational challenges that this condition may involve. For this reason, our commitment is focused on providing concrete and targeted solutions, helping patients regain confidence and a renewed sense of well-being.
Thanks to our Medical Director, Dr. Giovanni Menchini, and his twenty years of experience in the treatment of vitiligo, Dermacademy represents a unique point of reference in Italy. The ImmunoNova protocol, developed by the Institute’s medical team, is today considered the most advanced and personalized clinical method available: a systemic approach that does not simply treat the skin, but acts on the root cause of the disease by rebalancing the entire body.
The two main forms of vitiligo are:
- Bilateral (or non-segmental) vitiligo: the patches develop symmetrically on both sides of the body, often in a slow and unpredictable manner.
- Segmental vitiligo: appears asymmetrically on only one side of the body, generally at a young age, with patches that become white immediately.
Vitiligo and Emotional Impact
The psychological consequences of vitiligo, especially when it affects the face or visible areas of the body, can be significant. Dermacademy’s goal is not only to treat the skin, but also to help people regain self-confidence and peace of mind in everyday life.
The causes of vitiligo are not yet fully understood, but research has identified several related factors:
- Heredity: genetic predisposition appears to play an important role.
- Thyroid disorders: thyroid-related conditions may influence the appearance of the spots.
- Stress and immune system: periods of significant stress or a weakened immune system may contribute to the onset of vitiligo.
Dr. Giovanni Menchini, with more than twenty years of experience in the study of vitiligo, has dedicated his career to understanding and fighting this disease, developing innovative methods to improve patients’ quality of life.
It is with this vision that, at the Dermacademy Institute in Pisa, we developed ImmunoNova, an advanced protocol for the treatment of vitiligo, created through the analysis of thousands of consultations and clinical data collected over recent years.
Many patients, often without realizing it, have already followed parts of this journey. Today, ImmunoNova represents a breakthrough because it does not simply treat the patches, but approaches vitiligo as a systemic autoimmune disease, in which the body’s balance plays a crucial role.
The most significant innovations include:
-
Leaky gut and microbiota
Intestinal permeability has been confirmed as a key factor in the activation of autoimmunity. ImmunoNova therefore places great emphasis on correcting gastrointestinal dysfunctions and restoring microbiota balance, both essential steps in reducing chronic inflammation. -
Reduction in the risk of other autoimmune diseases
Patients following the protocol, in addition to improving their vitiligo, show a significant reduction in the incidence of further autoimmune conditions.
Alongside these aspects, ImmunoNova also integrates:
-
a comprehensive clinical evaluation using the Vitiligo Activity Index and Wood’s lamp photography,
-
the targeted use of Vitamin D3 as an immune modulator,
-
daily home-based NB-UVB phototherapy, administered in precise and safe doses,
-
selected topical therapies to stimulate melanocytes and promote repigmentation.
The result is an approach that not only treats vitiligo and stimulates repigmentation, but also helps to protect the patient’s overall health.
ImmunoNova is not just a new protocol: it is a shift in perspective, allowing vitiligo to be addressed in a more comprehensive way, with benefits that go beyond the skin.
ImmunoNova is a therapeutic pathway designed to treat vitiligo as a systemic condition, not simply as a skin disorder.
The protocol works simultaneously on three levels – the gut, the immune system, and the skin – to correct the mechanisms that cause the destruction of melanocytes and promote repigmentation.
Vitiligo is an autoimmune disease: due to a recognition error, the immune system attacks melanocytes as if they were foreign cells.
This abnormal response may be triggered by intestinal alterations or by chronic low-grade inflammation that keeps the immune system in a constant state of alert.
Gut health and immune health are closely connected.
When the intestinal barrier becomes permeable (“leaky gut”), food particles or toxins can pass into the bloodstream, generating systemic inflammation that may trigger an autoimmune response.
Rebalancing the microbiota and restoring intestinal integrity are therefore integral parts of the ImmunoNova protocol.
ImmunoNova combines systemic and dermatological therapy.
It includes rebalancing the intestinal microbiota through targeted nutrition and supplementation, supporting immune modulation with Vitamin D3, and using NB-UVB phototherapy in sub-erythematogenic doses to stimulate skin repigmentation.
The result is a progressive and stable improvement in skin pigmentation.
The duration varies depending on the extent and activity of the vitiligo.
On average, a complete treatment cycle lasts from 2 to 4 months, with continuous clinical monitoring and personalized therapies.
In cases of active disease, additional maintenance phases may be recommended.
The first signs of repigmentation may appear after a few weeks of treatment, particularly around hair follicles or along the edges of the patches.
The response is individual and depends on factors such as age, disease activity, and consistency in following the protocol.
ImmunoNova does not simply mask the symptoms, but aims to interrupt the autoimmune mechanisms that drive the disease.
The goal is to stabilize vitiligo, reduce the risk of recurrence, and promote long-lasting repigmentation.
The protocol is recommended for patients with active or stabilized vitiligo, regardless of skin phototype.
An initial evaluation by a specialist physician is essential to define the most appropriate strategy and the correct therapeutic sequence.
The protocol uses safe and well-established methods: NB-UVB phototherapy, nutritional supplementation, and natural immunomodulating substances.
Any side effects are rare and temporary (such as mild erythema or skin dryness) and are managed with medical support.
Because ImmunoNova does not treat vitiligo as an aesthetic issue, but as a complex autoimmune disease.
The protocol works on interconnected organs and functions – the gut, the immune system, and the skin – restoring biological balance and immune tolerance.
Yes. Depending on the stage of the disease, ImmunoNova can be combined with localized phototherapy, topical treatments, or complementary regenerative therapies, always under medical supervision.
Book a specialist consultation
If you would like to learn more about how to fight vitiligo or if you are looking for an innovative and personalized treatment, book a consultation at the Dermacademy Institute. Thanks to the ImmunoNova protocol and the experience of Dr. Giovanni Menchini, vitiligo is a challenge that can be successfully addressed.